In a crossover design study, we compared the plasma bactericidal activities of erythromycin estolate (500 mg) and erythromycin ethylsuccinate (600 mg) after administration of a single oral dose to 12 healthy volunteers. Both erythromycin esters displayed very good plasma bactericidal activities against Streptococcus pneumoniae. The median bactericidal titers produced in plasma against Streptococcus pyogenes and Streptococcus pneumoniae were significantly higher with erythromycin estolate than with the ethylsuccinate ester at both 2 and 8 h after dosing (P < 0.05 by Student's t test). Both erythromycin esters showed rather weak bactericidal activity against Branhamella catarrhalis; a further look at these results indicated that erythromycin estolate presented 50% of the plasma samples at 2 h with bactericidal titers superior or equal to 1:8, versus 11% for the ethylsuccinate ester. Of the 60 plasma bactericidal activity tests performed against Staphylococcus aureus, only 6 (10%) and 3 (5%) exhibited titers of 1:8 or greater for erythromycin estolate and erythromycin ethylsuccinate, respectively. Clinical trials are warranted in which these two products are compared in infections other than Streptococcus pyogenes pharyngitis, for which the clinical superiority of erythromycin estolate has been demonstrated.
The merits of various oral erythromycin products have been debated for several years (6) . Erythromycin esters such as the estolate (laurylsulfate salt of propionate) and ethylsuccinate must be hydrolyzed to the erythromycin base to become active (13) . The esters themselves (nonhydrolyzed) possess some antimicrobial activities, but they can hardly be quantitated (1, 12) . Some controversy exists over the purported superiority of erythromycin estolate in yielding higher concentrations of erythromycin base in serum than other forms of erythromycin. Some investigators have suggested that this difference can be attributed to the more complete hydrolysis of erythromycin estolate during the blood level microbioassay procedure than what is really occurring in the body (10, 11) . A recent pharmacokinetic study using a high-pressure liquid chromatographic (HPLC) assay method, which achieved the separation of the esters and the erythromycin base, has shown that erythromycin estolate yields an area under the curve of erythromycin base which is 3 times higher than that obtained with the ethylsuccinate form (2) .
Here we report the plasma bactericidal activities of erythromycin estolate and erythromycin ethylsuccinate against clinical isolates of Streptococcus pyogenes, Branhamella catarrhalis, Streptococcus pneumoniae, and Staphylococcus aureus.
MATERIALS AND METHODS
Subjects and study design. Twelve healthy volunteers (three females and nine males) between the ages of 18 and 39 years (mean age, 23.8 ± 6.9 years) gave written informed consent to participate in the study. The protocol was approved by Le Centre Hospitalier de l'Universitd Laval Human Research Review and Pharmacology-Therapeutics committees. The mean weight of the subjects was 69.2 ± 9.8 kg (range, 53.5 to 87.0 kg). All subjects were judged to be * Corresponding author.
healthy on the basis of history, physical examination, chemistry profile, complete blood count, and urinalysis. None had a history of hepatic, renal, or neoplastic diseases or known previous allergies to macrolide compounds. No medication was allowed at the time of study. Alcoholic beverages were withheld 24 h before and during the study. Volunteers had to refrain from any strenuous or athletic activity during the study period, but were allowed to circulate around the pharmacokinetic research unit.
After an overnight fast, each volunteer received orally, in a randomized crossover study, a single dose of erythromycin estolate (Ilosone tablet; 500-mg base equivalent; Eli Lilly Canada Inc., Toronto, Ontario, Canada) and erythromycin ethylsuccinate (E.E.S. tablet; 600-mg base equivalent; Laboratoires Abbott Limitee, Montreal, Quebec, Canada), which were taken with at least 150 ml of drinking water. A 2-h fast was observed after drug administration.
Plasma sampling. Blood samples were drawn from an intravenous catheter in an antecubital vein at 2 h (time of attainment of the maximal concentration in plasma) (2) and 8 h after the dose (the usual time interval of drug administration). A diluted heparin solution (33 U/ml) was used to maintain the patency of the catheter, and at least 1.5 ml of blood was removed and discarded before blood was drawn. Samples (10 ml) were collected into chilled VACUTAI-NERS (Becton Dickinson Vacutainer Systems, Rutherford, N.J.), which contained EDTA as an anticoagulant. The blood sample was immediately placed into an ice bath, until it was spun in a refrigerated centrifuge (900 x g for 10 min). The collected plasma was then frozen at -20°C for 2 months, until the plasma bactericidal activity test was performed.
Sample analysis. Plasma samples were analyzed for erythromycin base and erythromycin estolate or erythromycin ethylsuccinate by a reverse-phase HPLC procedure by using electrochemical detection, as developed in our laboratory (3) . This HPLC method measures erythromycin base and erythromycin esters in biological samples simultaneously. cinate concentrations and the erythromycin base generated by erythromycin ethylsuccinate hydrolysis were both under the sensitivity limit of the assay. Microbiological activities. The MICs and MBCs of both erythromycin esters against the microorganisms tested are displayed in Table 2 . Against Streptococcus pyogenes, Streptococcus pneumoniae, and Branhamella catarrhalis, erythromycin ethylsuccinate was somewhat more active than erythromycin estolate, with median MICs of less than 0.12 and 0.5 ,ug/ml, respectively. Erythromycin esters were less potent against Staphylococcus aureus; however, erythromycin ethylsuccinate was again more active than erythromycin estolate, with median MICs of 1 versus 8 pug/ml, respectively. For erythromycin ethylsuccinate, MBCs did not differ from the MICs for Streptococcus pyogenes and Streptococcus pneumoniae. Against Branhamella catarrhalis and Staphylococcus aureus, the median MBC of erythromycin ethylsuccinate was 3 to 4 times higher than the median MIC. MBCs of erythromycin estolate were similar to the median MICs against Streptococcus pneumoniae and were 1 to 2 times higher against the three other strains.
Plasma bactericidal activities. 32, 1988 0--i 0--i isms, the plasma bactericidal activity of erythromycin estolate was significantly greater than that of erythromycin ethylsuccinate (P < 0.01 by Student's t test) both at the time of peak levels (2 h) and at the end of the dosing interval (8 h).
The plasma bactericidal activity results at 2 and 8 h after dosing reflected the poor activity of erythromycin esters against Staphylococcus aureus. Therefore, our data support the revised criteria for erythromycin susceptibility testing based on achievable levels in serum suggested by Jones et al. (9) .
Based on the results of in vitro susceptibility testing of these two esters, better plasma bactericidal activity would have been expected from the ethylsuccinate form. Erythromycin ethylsuccinate rated better during susceptibility testing because it is hydrolyzed in vitro more rapidly and more extensively than the estolate form (13) . In addition, more erythromycin base is available on a weight basis from erythromycin ethylsuccinate standard powder since its molecular weight is 861, versus 1,056 for the estolate form. However, the estolate form achieved significantly greater plasma bactericidal activity, mainly because it attained higher concentrations of erythromycin base in plasma (Tables 1 and 3).
Since the presence of intrinsic antibacterial effects in the plasma of the volunteers was not ruled out, it is possible that these plasma samples did contain antibodies against some serotypes of the microorganisms tested. During the 20-h incubation period of the plasma bactericidal activity measurement, the hydrolysis of erythromycin esters occurred and contributed to the overestimate of the bactericidal titer. Nevertheless, both esters were submitted to the same procedure.
In summary, erythromycin estolate is significantly more active than erythromycin ethylsuccinate at 2 and 8 h after administration against Streptococcus pyogenes, Branhamella catarrhalis, and Streptococcus pneumoniae. Therefore, clinical trials are warranted in which these two products can be compared against infections other than Streptococcus pyogenes pharyngitis.
